8-KLeadership ChangesShareholder MattersExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Executive Changes (Jun 5, 2024)

Filed June 5, 2024For Securities:ONCBEIGF

Summary

BeiGene, Ltd. (ONC) filed an 8-K on June 5, 2024, detailing the outcomes of its 2024 Annual General Meeting of Shareholders. The most significant investor-focused updates involve the shareholder approval of amendments to key equity incentive plans. Specifically, the Third Amended and Restated 2016 Share Option and Incentive Plan and the Fourth Amended and Restated 2018 Employee Share Purchase Plan were approved. These amendments, driven by changes in Hong Kong Listing Rules, include substantial increases in the number of shares available for issuance under these plans. The former plan now has an additional 92,820,000 shares available, while the latter has an additional 5,070,000 shares available. Furthermore, the meeting saw the re-election of several Class II directors, including Dr. Olivier Brandicourt, Mr. Donald W. Glazer, Mr. Michael Goller, and Dr. Corazon (Corsee) D. Sanders, all approved by significant margins. The company also received shareholder approval for a general mandate to issue up to 20% of its outstanding shares and a mandate to repurchase up to 10% of its outstanding shares, providing flexibility for capital management. Additionally, significant grants of Restricted Share Units (RSUs) and Performance Share Units (PSUs) to named executive officers, including CEO John V. Oyler and Dr. Xiaodong Wang, were approved, along with advisory votes on executive compensation and the frequency of future say-on-pay votes, which will be held annually.

Key Highlights

  • 1Shareholders approved the Third Amended and Restated 2016 Share Option and Incentive Plan, increasing the share pool by 92,820,000 shares.
  • 2Shareholders approved the Fourth Amended and Restated 2018 Employee Share Purchase Plan, increasing the share pool by 5,070,000 shares.
  • 3Dr. Olivier Brandicourt, Mr. Donald W. Glazer, Mr. Michael Goller, and Dr. Corazon (Corsee) D. Sanders were re-elected as Class II directors.
  • 4A general mandate was approved, allowing the Board to issue up to 20% of outstanding shares.
  • 5A general mandate was approved, allowing the Board to repurchase up to 10% of outstanding shares.
  • 6Shareholder approval was granted for significant RSU and PSU grants to executive officers, including CEO John V. Oyler and Dr. Xiaodong Wang.
  • 7An advisory vote on named executive officer compensation was approved, and shareholders voted for annual 'say-on-pay' votes.

Frequently Asked Questions